ArticleAnnals of surgical oncology2026
Prognostic Impact of Cachexia Index in Patients Undergoing Surgery for Esophageal Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Positioning the Cachexia Index in the Prognostic Landscape of Esophageal Cancer Surgery.Annals of surgical oncology · 2026Article
- A LASSO-based nomogram for predicting sarcopenia-related nutritional risk in esophageal cancer patients: model development, validation, and an interactive clinical decision tool.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCachexia index (CXI) is a recently proposed biomarker reflecting the cachectic condition, including inflammation, sarcopenia and nutritional status, of patients with various malignancies. We evaluated its prognostic impact in patients undergoing esophagectomy for esophageal cancer (EC).
methodsA total of 378 patients were retrospectively reviewed. CXI was calculated as skeletal muscle index × serum albumin level/neutrophil-to-lymphocyte ratio. The sex-specific lowest quartile defined the Low-CXI group. Univariate and multivariate Cox proportional hazards models were applied to identify independent prognostic factors for overall survival (OS) and disease-free survival (DFS).
resultsThe low-CXI group was significantly associated with older age (P < 0.001), more severe comorbidity (P = 0.001), and more advanced pathological stage (P = 0.032). Patients in the low-CXI group had poorer OS and DFS than those in the high-CXI group (both P < 0.001). Multivariate analysis revealed that low-CXI was independently associated with poor OS (P = 0.002) and DFS (P = 0.002). In the cause-specific survival analyses, low-CXI was a predictor of deaths from non-EC-related causes. Subdivision into pathological stage (pStage) 0-I and II/III revealed that significant survival differences according to CXI were observed in both pStage 0-I (P = 0.045 for OS, and 0.029 for DFS) and pStage II/III (P < 0.001 for OS, and 0.002 for DFS) patients.
conclusionsLow-CXI was independently associated with poor OS and DFS in patients undergoing surgery for EC, in both early- and advanced-stage patients. Furthermore, CXI may also be useful for predicting non-EC-related mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.